MX9300620A - Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona. - Google Patents

Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.

Info

Publication number
MX9300620A
MX9300620A MX9300620A MX9300620A MX9300620A MX 9300620 A MX9300620 A MX 9300620A MX 9300620 A MX9300620 A MX 9300620A MX 9300620 A MX9300620 A MX 9300620A MX 9300620 A MX9300620 A MX 9300620A
Authority
MX
Mexico
Prior art keywords
aerosol
administration
pharmaceutical formulation
inhaler
monohydrate
Prior art date
Application number
MX9300620A
Other languages
English (en)
Inventor
Philip John Neale
Anthony James Taylor
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX9300620A publication Critical patent/MX9300620A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a las formulaciones en aérosol de uso para la administración de medicamentos mediante inhalación, en particular una formulación farmacéutica en aérosol que comprende: (a) di-propionato de beclometasona monohidratado, el tamaño de partícula de todo el monohidrato substancialmente es menor de 20 micras; (b) al menos 0.015 en peso de la formulación de agua además del agua de cristalización asociada con dicho monohidrato; y (c) un fluorocarburo o propelente de cloro-fluoro-carburo que contiene hidrógeno. Se describe también un método para el tratamiento de transtornos respiratorios, que comprenden la administración mediante inhalación de una cantidad efectiva de una formulación farmacéutica en aérosol.
MX9300620A 1992-02-06 1993-02-04 Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona. MX9300620A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929202519A GB9202519D0 (en) 1992-02-06 1992-02-06 Medicaments

Publications (1)

Publication Number Publication Date
MX9300620A true MX9300620A (es) 1993-08-01

Family

ID=10709929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9300620A MX9300620A (es) 1992-02-06 1993-02-04 Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.

Country Status (31)

Country Link
US (2) US5695744A (es)
EP (1) EP0625046B1 (es)
JP (1) JP3675474B2 (es)
CN (1) CN1048394C (es)
AP (1) AP419A (es)
AT (1) ATE157875T1 (es)
AU (1) AU667074B2 (es)
BG (1) BG61862B1 (es)
CA (1) CA2128688A1 (es)
CZ (1) CZ281942B6 (es)
DE (1) DE69313825T2 (es)
DK (1) DK0625046T3 (es)
ES (1) ES2106360T3 (es)
GB (1) GB9202519D0 (es)
GE (1) GEP19991820B (es)
GR (1) GR3025363T3 (es)
HK (1) HK1009588A1 (es)
HU (2) HUT68986A (es)
IL (1) IL104628A (es)
IS (1) IS1622B (es)
MX (1) MX9300620A (es)
MY (1) MY108748A (es)
NO (1) NO306453B1 (es)
NZ (1) NZ246889A (es)
OA (1) OA10091A (es)
RO (1) RO118173B1 (es)
RU (1) RU2120285C1 (es)
SK (1) SK279291B6 (es)
TW (1) TW299234B (es)
WO (1) WO1993015741A1 (es)
ZA (1) ZA93800B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919435A (en) * 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
WO1993011744A1 (en) 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
EP0717987B1 (en) 1991-12-18 2001-08-29 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US5833950A (en) * 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
MY131733A (en) * 1994-12-22 2007-08-30 Astra Ab Aerosol drug formulations
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
IL122752A (en) 1995-06-27 2001-07-24 Boehringer Ingelheim Kg Stable preparations for creating propellant-free sprays
IL130872A (en) * 1997-01-14 2004-02-19 Lohmann Therapie Syst Lts Device for controlled release of active compounds in the connection of the stomach and intestines containing an expanding component
KR20000076420A (ko) * 1997-03-18 2000-12-26 스타르크, 카르크 코르티코스테로이드에 대한 반응성을 조절하기 위한 방법 및 조성물
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
TWI243687B (en) * 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US6540982B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6540983B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6565833B1 (en) 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6447750B1 (en) 2000-05-01 2002-09-10 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6548049B1 (en) 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
MXPA02001323A (es) 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
AU2001247123A1 (en) * 2000-07-19 2002-02-05 Aeropharm Technology, Inc. A medicinal aerosol formulation
WO2002011711A2 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
AU2007231727B2 (en) * 2002-09-03 2010-12-16 Kos Life Sciences, Inc. Water stabilized medicinal aerosol formulation
UA89751C2 (ru) * 2003-03-20 2010-03-10 Бёрингер Ингельхайм Фармасьютикалз, Инк. Состав, который содержит сульфат альбутерола и бромид ипратропия, способ его получения и ингалятор
US20040191176A1 (en) * 2003-03-28 2004-09-30 Kaplan Leonard W Formulations for treatment of pulmonary disorders
WO2005023330A2 (en) * 2003-08-29 2005-03-17 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
US20050238632A1 (en) * 2004-04-23 2005-10-27 Alburty David S Propellant formulations
EP1809243B2 (de) 2004-07-02 2022-06-08 Boehringer Ingelheim International GmbH Aerosolsuspensionsformulierungen mit tg 227 ea als treibmittel
US9084799B2 (en) 2005-02-11 2015-07-21 Pulmagen Therapeutics (Synergy) Limited Inhaled combination therapy
SI1845994T1 (sl) 2005-02-11 2009-06-30 Argenta Discovery Ltd Kombinacija metilksantinskih spojin in steroidov za zdrvljenje kroničnih respiratornih bolezni
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
EP2120875B1 (en) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
RU2504402C1 (ru) * 2012-11-20 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный состав в форме аэрозоля для лечения бронхиальной астмы и хронической обструктивной болезни легких

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI63672C (fi) * 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
WO1992006675A1 (en) * 1990-10-18 1992-04-30 Minnesota Mining And Manufacturing Company Aerosol formulation comprising beclomethasone 17,21 dipropionate

Also Published As

Publication number Publication date
ATE157875T1 (de) 1997-09-15
SK92494A3 (en) 1995-04-12
GR3025363T3 (en) 1998-02-27
BG61862B1 (bg) 1998-08-31
OA10091A (en) 1996-12-18
RU2120285C1 (ru) 1998-10-20
HUT68986A (en) 1995-08-28
AP419A (en) 1995-10-24
HU9402301D0 (en) 1994-10-28
CZ184694A3 (en) 1995-03-15
US5695744A (en) 1997-12-09
AU3452593A (en) 1993-09-03
NO942923L (no) 1994-08-05
AP9300484A0 (en) 1993-04-30
CN1078633A (zh) 1993-11-24
CA2128688A1 (en) 1993-08-19
GB9202519D0 (en) 1992-03-25
IL104628A (en) 1998-12-27
DK0625046T3 (da) 1998-04-27
EP0625046B1 (en) 1997-09-10
NO306453B1 (no) 1999-11-08
NO942923D0 (es) 1994-08-05
IS1622B (is) 1996-10-18
JP3675474B2 (ja) 2005-07-27
ZA93800B (en) 1993-10-06
MY108748A (en) 1996-11-30
BG98897A (bg) 1995-02-28
GEP19991820B (en) 1999-11-05
DE69313825T2 (de) 1998-02-05
US5688782A (en) 1997-11-18
WO1993015741A1 (en) 1993-08-19
DE69313825D1 (de) 1997-10-16
TW299234B (es) 1997-03-01
IS3974A (is) 1993-08-07
JPH07503476A (ja) 1995-04-13
NZ246889A (en) 1996-11-26
RO118173B1 (ro) 2003-03-28
HU211696A9 (en) 1995-12-28
ES2106360T3 (es) 1997-11-01
CN1048394C (zh) 2000-01-19
AU667074B2 (en) 1996-03-07
SK279291B6 (sk) 1998-09-09
CZ281942B6 (cs) 1997-04-16
IL104628A0 (en) 1993-06-10
EP0625046A1 (en) 1994-11-23
HK1009588A1 (en) 1999-06-04

Similar Documents

Publication Publication Date Title
MX9300620A (es) Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.
CY1122851T1 (el) Υπερλεπτο σκευασμα φορμοτερολης
MX9304585A (es) Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
NO20065102L (no) Medikamenter
CA2125666A1 (en) Medicaments
CO5031245A1 (es) Inhaladores de dosis regulada a presion y formulaciones farmaceuticas de aerosol
DK0656207T4 (da) Aerosolformuleringer uden chlorfluorcarbonforbindelser
CA2125665A1 (en) Medicaments
AR009231A1 (es) Formulaciones en aerosol de formoterol.
ATE216575T1 (de) Treibgasmischung für eine aerosolzubereitung
ES2150022T3 (es) Aerosol farmaceutico que contiene al menos un azucar.
IT1303788B1 (it) Formulazioni di aerosol medicinali.
AR022090A1 (es) PARTíCULAS PARA LA ADMINISTRACIoN DE UN AGENTE ACTIVO A LOS ALVÉOLOS DE UN PACIENTE HUMANO, UN MÉTODO PARA SU PREPARACIoN, Y EL USO DE LAS MISMAS PARA LA PREPARACIoN DE UN MEDICAMENTO PARA INHALACIoN
BG107257A (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
TH51541A (th) สารผสมใหม่ของเนื้อสาร

Legal Events

Date Code Title Description
FG Grant or registration